systolic

• Business

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…